119 results about "Transmembrane protein" patented technology

The invention discloses a composite antibacterial preparation containing antibacterial peptide and traditional Chinese medicines as well as a preparation method and application of the composite antibacterial preparation, and belongs to the technical field of biological medicines. The antibacterial peptide provided by the invention is a transmembrane protein derived from bacteriophage, and the core function of the antibacterial peptide is that bacterial cell lysis is promoted by destroying a connection structure of a peptidoglycan layer and lipoprotein of a bacterial cell wall, so that an antibacterial effect is achieved. The amino acid sequence of the antibacterial peptide is shown as SEQ ID NO: 3, the antibacterial peptide is combined with traditional Chinese medicines to form a composite antibacterial preparation, and experiments prove that the composite antibacterial preparation has a relatively good antibacterial effect on gram-positive bacteria and gram-negative bacteria and can be applied to the medical field, such as surgical instrument disinfection and drug-resistant bacterial infection treatment; the field of daily chemicals, such as antibacterial hand sanitizers and wound dressings; in the field of agriculture, for example, animal feed additives for preventing and treating intestinal infection have a good market application prospect.

The invention belongs to the technical field of collagen skin care products, and provides an oil-soluble recombinant collagen bionic nano-liposome delivery system and a preparation method and application thereof.The preparation method comprises the steps that A, a buffer solution with the pH being 3.8-4.2 is added into a lipid film, oscillation and ultrasonic treatment are conducted, and blank liposome is obtained; b, dissolving the integrin alpha6beta4 transmembrane protein by using a buffer solution with the pH value of 7.2-7.4; adding the transmembrane protein solution into blank lipidosome, oscillating and incubating at 37 DEG C, and performing ultrafiltration and centrifugation to obtain lipidosome suspension; c, dropwise adding the recombinant collagen solution into the liposome suspension, stirring at a constant temperature of 40 + / -2 DEG C, and performing ultrasonic treatment to obtain a collagen liposome suspension; and D, homogenizing the collagen liposome suspension at high pressure, and performing ultrafiltration purification to obtain the purified collagen liposome suspension. Through the technical scheme, the problems of low collagen encapsulation efficiency and low transdermal efficiency in the prior art are solved.

Provided herein are transmembrane proteins containing a cytokine or a functional portion thereof, such as an interleukin or a functional portion thereof. In some aspects, the disclosure further relates to engineered cells and compositions comprising the transmembrane proteins and methods for their administration to subjects. In some embodiments, the cells engineered to contain the transmembrane protein, such as immune cells, further contain a genetically engineered recombinant receptor, such as a chimeric antigen receptor (CAR). In some embodiments, features of the transmembrane proteins, engineered cells, and methods and uses thereof provide for improved treatment of diseases or disorders.

The invention discloses a preparation method of a monomeric protein and hydrophobic transmembrane protein complex, which comprises the following steps: 1) preparing a protein A containing the monomeric protein, the C end of the monomeric protein in the protein A having a connection sequence for connecting with the hydrophobic transmembrane protein; the connecting sequence comprises at least two amino acids; preparing a protein B containing a hydrophobic transmembrane protein monomer; and 2) connecting the protein A with the protein B, and polymerizing the hydrophobic transmembrane protein monomers in the plurality of protein B to form the hydrophobic transmembrane protein, thereby obtaining the monomeric protein and hydrophobic transmembrane protein complex.

The invention relates to a transmembrane protein and transmembrane protein interaction prediction method, computer equipment and a storage medium, and the method comprises the steps: inputting an amino acid sequence 1 of protein 1 and an amino acid sequence 2 of protein 2 into a transmembrane prediction neural network, and when an output result identifies that the two proteins are transmembrane proteins, determining the transmembrane protein interaction between the two proteins; screening an extracellular amino acid fragment sequence 1 of the protein 1 and an extracellular amino acid fragment sequence 2 of the protein 2 from output results of the transmembrane prediction neural network; the extracellular amino acid fragment sequence 1 and the extracellular amino acid fragment sequence 2 are input into a trained attention mechanism model, an interaction score is obtained, and the interaction score is used for representing the interaction possibility of the protein 1 and the protein 2. According to the method, the interaction between the transmembrane protein and the transmembrane protein is automatically determined in a computer mode, and excessive manpower and material resources do not need to be consumed.

The invention belongs to the technical field of medical chemistry, and particularly relates to a targeted protein degradation compound containing an SYVN1 binding compound and application of the targeted protein degradation compound. According to the invention, a series of compounds interacting with SYVN1 are found, and the compounds can be used as'warheads' to participate in ERAD and effectively degrade transmembrane protein targets. Based on the SYVN1 binding compound, a new TPD technology for hijacking ERAD is established, and a brand new platform is provided for processing TMSPs and other proteins which are difficult to target by the current TPD technology. A SYVN1 interaction compound is further connected with a known ligand interacting with a protein target through a chemical linker, a series of ERADEC molecules are generated, the molecules can significantly degrade target protein, and a new possibility is provided for targeted degradation of drugs.

The invention belongs to the technical field of medicines, and particularly relates to application of isodan leaf emodin in preparation of an Icam1 inhibitor, related experiments of establishment of a sepsis liver injury model induced by cecum ligation puncture (CLP) show that by applying the isodan leaf emodin, the Icam1 inhibitor can be used for preparing Icam1. According to the present invention, the level of liver tissue proinflammatory factors TNF-alpha, IL-1beta and IL-6 in the liver injury caused by sepsis is reduced, the level of the anti-inflammatory factor IL-10 is increased, and the HE dyeing of the liver tissue proves that the emodin can alleviate the CLP induced inflammatory cell infiltration in the liver tissue, can protect the structural integrity of the liver tissue, and can provide the anti-inflammatory effect on the liver tissue, such that the liver injury caused by sepsis can be inhibited, and the liver injury caused by sepsis can be inhibited. The data shows that the isodan leaf emodin can relieve sepsis liver injury and reduce liver function indexes. In research, it is found for the first time that the action mechanism of the isodan-leaf emodin in relieving the sepsis liver injury is that liver function indexes and inflammatory response are relieved by inhibiting expression of a transmembrane protein intercellular adhesion molecule-1 (Icam1), and it is indicated that the isodan-leaf emodin has a good application prospect in treating sepsis-related tissue injury.

A targeting vehicles comprises an extracellular vesicle with a dopamine transporter antibody on a transmembrane protein of the extracellular vesicle, the extracellular vesicle is secreted by a cell transfected with a vector gene, and at least a portion of the vector gene comprises SEQ ID No: 1. The targeting vehicles provided in the present invention can be loaded with drugs and cross the blood-brain barrier to achieve specific binding to dopamine neuron, and regulate the secretion of Parkinson's disease marker proteins and delay the course of Parkinson's disease.

The present invention provides a long-acting dual-target chimeric antigen receptor, nucleic acid molecule, recombinant vector, cell, and application thereof. The dual-target chimeric antigen receptor comprises two independent transmembrane protein chains, wherein the first CAR chain targets a scFv of the first target, and the intracellular signal comprises a second signal and an intracellular transduction signal or only an intracellular transduction signal; the second CAR chain targets a scFv of the second target, and the intracellular signal comprises a costimulatory signal and a JAK enzyme activation transduction domain. The CAR-T cells prepared by the present invention have a strong and persistent killing effect on tumor cells that simultaneously express the first and second targets, and can be used for the anti-tumor treatment of solid tumors.

The present application relates to the field of biotechnology, in particular to a kit based on functionalized magnetic beads and application thereof in the field of stem cells. The functionalized magnetic beads of the present application are loaded with extracellular matrix proteins on the surface, and the extracellular matrix proteins are selected from collagen. The functionalized magnetic beads of the present application realize efficient capture and enrichment of collagen-bound transmembrane proteins, combined with mass spectrometry identification, and are suitable for screening stem cell transmembrane proteins, studying the action sites of stem cells and matrix, or developing drugs targeting stem cells. The kit and method of the present application have the technical advantages of simple operation, good stability and strong specificity, and provide a powerful tool for systematic study of the cell-matrix interaction mechanism mediated by stem cell transmembrane proteins.

Methods and compositions for treating a corneal wound and / or increasing a population of limbal epithelial stem cells (LESCs) and / or early transit amplifying cells (eTAs) in the limbal epithelium of a subject in need thereof. The methods can include administering a therapeutic agent to the subject that: i) results in an increase in concentration of IFITM1 (Interferon Induced transmembrane Protein 1) in the limbal epithelium of the subject; and / or ii) results in a decrease in concentration of OVOL1 (Ovo Like Zinc Finger 1) in the limbal epithelium of the subject. Also provided are adeno-associated viruses (AAVs). The AAVs comprise a heterologous nucleic acid sequence encoding IFITM1 or a variant thereof, operably linked to a regulatory sequence.

The application discloses a kind of bionic transmembrane protein affinity chromatography column and its preparation method and application.The system (iSTAC) realizes the in-situ construction of transmembrane protein in highly bionic dynamic microenvironment by integrating cell-free protein synthesis, functional mesoporous silica modification and amphiphilic (AH) peptide stabilized planar lipid bilayer technology.The core is to use long-chain PEG-24 crosslinking agent to retain lipid bilayer on the surface of silica gel, provide sufficient conformational dynamic space for multi-transmembrane protein, and introduce AH peptide to repair membrane defects, ensure that the receptor realizes directional embedding while maintaining natural functional attributes.The preparation cycle is shortened from 168 hours to 5 hours, which significantly improves the efficiency of targeted drug screening and in-situ analysis of binding sites.Using this platform, 5-HT 1A Receptor agonists crocin I and crocin II with anti-insomnia and neuroprotective effects are successfully screened from saffron, and the action site is accurately depicted.

The invention relates to the technical field of exosome synthesis, and discloses a method for measuring exosome synthesis efficiency. According to the method, by utilizing the characteristic that four-transmembrane proteins in different types of cells are different in content, various four-transmembrane proteins are selected as calibration substances, and part of the four-transmembrane proteins are used as internal reference, so that in the process of determining the exosome synthesis efficiency, the content of the four-transmembrane proteins in the exosome synthesis efficiency is determined. According to the method, the expression level of the tetratransmembrane protein calibration substance in the cell membrane can be equalized by using the total tetratransmembrane protein, so that the problem of inaccurate determination of the exosome synthesis efficiency caused by difference between cell types is remarkably improved, and accurate determination of the exosome synthesis efficiency of different types of cells can be realized; and the determination method is simple and easy to operate, low in cost, high in speed and suitable for large-scale application in exosome synthesis efficiency determination, and has important significance in large-scale synthesis and commercial application of the exosome.

The application discloses an exosome drug delivery system with anti-phagocytosis and tumor targeting ability as well as a preparation method and application thereof. A tumor targeting group is flexibly connected to the outside of the cell membrane of a transmembrane protein with anti-phagocytosis ability through a linker of a fusion protein. A fusion gene sequence is designed and inserted into an expression vector to form a fusion expression vector, which is integrated into the chromosome of a cell to be modified to obtain an engineered cell stably expressing the fusion protein, which is used for secreting engineered exosomes. The cell to be modified includes a naked cell (an immortalized cell line, a primary cell), an engineered cell stably expressing a therapeutic nucleic acid molecule or a protein. The exosomes produced by the former cell can further package the therapeutic molecules to treat tumors, and the exosomes produced by the latter cell can be directly used for treating tumors after being separated, purified and collected. The half-life of the engineered exosomes produced by the application is significantly prolonged in the body, the treatment effect is improved, and the exosomes show strong tumor targeting and anti-tumor effects in vivo and in vitro.

The invention relates to the technical field of biological detection, in particular to a method for detecting exfoliation of a membrane protein based on double-color co-localization, which comprises the following steps: firstly, providing a double-labeled probe which is a fusion protein and comprises a first detectable label, a transmembrane protein or a transmembrane fragment thereof and a second detectable label which are connected in sequence; the first detectable label and the second detectable label are different. According to the present invention, the double-labeled probe is expressed by the host cell, and the first detectable label and the second detectable label are detected in real time, such that the exfoliation ratio and the exfoliation time of the membrane protein can be analyzed in situ, and the method has excellent detection sensitivity and time resolution.

The application provides a screening method of human amniotic membrane mesenchymal stem cells (hAMSCs) with bone regeneration promoting potential, and uses the protein level of transmembrane protein 119 (TMEM119) as a functional index of the bone regeneration promoting ability of the hAMSCs, and uses an enzyme-linked immunosorbent assay (ELISA) to detect the TMEM119 protein concentration in a lysis solution prepared from 1×10 7 The application uses the TMEM119 protein concentration not lower than 15000 pg / mL as a screening standard of the hAMSCs with bone regeneration promoting potential, and screens the hAMSCs with significant bone regeneration promoting potential from different batches of hAMSCs, so that the hAMSCs meeting the screening standard of the application have obvious bone formation promoting potential, and the technical problem that the hAMSCs with bone regeneration promoting potential are difficult to be accurately identified and screened in clinical transformation is solved.

The invention provides an engineering exosome drug delivery system for over-expression of CD24 and a preparation method thereof, and belongs to the technical field of gene engineering. CD24 is overexpressed on a membrane of the engineered exosome, and a gene sequence of a plasmid of the overexpressed CD24 is as shown in SEQ ID No. 1; a CD24 sequence is fused to the N end of an I-type transmembrane protein structure LAMP2B on a membrane of the engineered exosome, a glycosylation sequence GNSTM is introduced to the N end of the fusion sequence, and an exosome binding peptide Signal peptide fragment is fused to the N end of the glycosylation sequence GNSTM. The engineering exosome for over-expressing CD24 on an exosome membrane is successfully constructed by using a fusion gene for coding transmembrane proteins LAMP2B and CD24, the aggregation and protein adsorption phenomena of the engineering exosome can be effectively retarded, the drug delivery targeting of the engineering exosome is enhanced, the in-vivo duration of the engineering exosome is prolonged, and the delivery performance of the engineering exosome is further improved.

A low immunogenic exosome-based RNA package and delivery system capable of delivering a cargo RNA to a target site. In an embodiment, the low immunogenic exosome- based RNA package and delivery system comprises an exosome producing cell, one or more cargo RNA encoding plasmids and one or more fusion protein encoding plasmids, wherein the cargo RNA comprises a package RNA and a packaging domain and wherein the package fusion protein comprises an exosome associated transmembrane protein fused to a packaging protein. The present invention also provides an exosome composition comprising an exosome encapsulating a cargo RNA and a package fusion protein wherein the cargo RNA and the package fusion protein binds via the packaging domain and the packaging protein to form cargo RNA fusion protein complex. In an embodiment the packaging protein is endogenous to a subject. The present invention also provides a method of preparation of the exosome composition.

The invention discloses a multi-source vegetable outer vesicle composition as well as a preparation method and application thereof. The multi-source vegetable outer vesicle composition is prepared from outer vesicles extracted from spinach leaves, ginger tubers, broccoli buds, bitter gourd fruits and celery stems. The spinach leaves, the ginger tubers, the broccoli flower buds, the bitter gourd fruits and the celery stems are mixed according to the fresh weight ratio of (3-5): (1-2): (2-3): (1-1.5): (2-4), and low-temperature homogenization, centrifugation and ultrafiltration purification are performed to obtain the spinach-ginger-containing beverage. The particle size of the multisource vegetable outer vesicle composition is 100-200 nm, and the multisource vegetable outer vesicle composition comprises transmembrane protein TET8 and membrane anchoring protein ANNEXIN, and further comprises active ingredients of miR159a, miR166a, quercetin and kaempferol. The outer vesicle can target a PPAR gamma / FAS pathway and regulate and control lipolysis and metabolism reprogramming of fat cells; meanwhile, an Nrf2 pathway is activated, free radicals are removed, oxidative stress injury is inhibited, and metabolic diseases such as obesity, type II diabetes mellitus and non-alcoholic fatty liver disease can be effectively improved.

The invention discloses a preparation method of a nano-enzyme preparation as well as a product and application of the nano-enzyme preparation. The synthesis method of the nano-enzyme preparation comprises the following steps: mixing a transmembrane protein solution and a solution containing one or more nano-enzymes to prepare the nano-enzyme preparation. The nano-enzyme can target a disease site, and on one hand, the nano-enzyme removes active oxygen and active nitrogen species on the disease site; on the other hand, the nano-enzyme can be combined with cytokines of disease parts, the promotion effect of the cytokines on diseases is inhibited, and the effect of preventing and treating colitis and colitis-related colon cancer diseases is achieved. The nano-enzyme developed by the invention not only can relieve oxidative stress of diseases, but also can reduce the pro-inflammatory and tumor-promoting effects of cytokines, and can effectively treat colitis-related colon cancer caused by deterioration of colitis.

Disclosed herein is an artificial transmembrane protein for use in a biomolecule detection device for detecting intracellular or intravesicular biomolecule interactions, the artificial transmembrane protein comprising an extracellular or extravesicular binding structure, a hydrophobic transmembrane domain, and an intracellular or intravesicular domain having an intracellular or intravesicular receptor structure, wherein the receptor structure is configured to interact with an intracellular or intravesicular component of a biomolecule interaction to be detected, and wherein the extracellular or extravesicular binding structure is configured to bind to a membrane recognition element arranged along a plurality of predetermined lines of the biomolecule detection device.

The present invention relates to engineered SIRP alpha variants and methods of use thereof. Signal regulatory protein a (SIRPa) is a regulatory membrane glycoprotein of the SIRP family. The protein is mainly expressed by bone marrow cells and also expressed by stem cells or neurons. SIRPa is used as an inhibitory receptor and interacts with a widely expressed transmembrane protein CD47. The present disclosure relates to engineered SIRPa variants and methods of use thereof.

The present invention discloses a prokaryotic soluble expression method and application of a recombinant African swine fever virus EP153R subunit transmembrane protein, the amino acid sequence of which is shown in SEQ ID NO.3. The prokaryotic soluble expression method includes: 1) According to the codon preference characteristics of Escherichia coli, artificially optimize and synthesize the African swine fever virus EP153R protein coding gene, the amino acid sequence of which is shown in SEQ ID NO.3, and the gene sequence is shown in SEQ ID NO.1; 2) Clone the coding gene sequence of the African swine fever virus EP153R protein after codon optimization, as shown in SEQ ID NO.1, into a prokaryotic expression vector to obtain a recombinant plasmid containing the African swine fever virus EP153R subunit protein coding gene; 3) Expression and purification of the EP153R subunit transmembrane protein. The present invention can provide an African swine fever transmembrane protein EP153R subunit protein that can be mass-produced industrially, and the preparation method is simple and the cost is low, meeting the existing national standards.

The present disclosure relates, inter alia, to compositions and methods, including chimeric proteins, and nucleic acids encoding the chimeric proteins having a first domain comprising an extracellular domain of a first transmembrane protein, a first secreted protein, or a first membrane-anchored extracellular protein and a second domain comprising an extracellular domain of a second transmembrane protein, a second secreted protein, or a second membrane-anchored extracellular protein, in which either or both of the first domain and the second domain decreases self-directed immune system activity when bound to its ligand / receptor. Accordingly, the present disclosure find use in the treatment of autoimmune diseases, and particularly, inflammatory bowel diseases.

The invention relates to bacillus subtilis as well as a construction method and application thereof, and the bacillus subtilis is a gram-positive bacterium from soil, also belongs to one kind of probiotics, and has multiple benefits to a human body. The Irisin is a novel muscle factor which is generated by shearing a transmembrane fibronectin type III domain protein 5 (fibronectin type III domain-conforming protein 5, FNDC5) through a proteolytic enzyme, and has the effects of alleviating obesity, improving insulin resistance, resisting inflammation and the like. According to the invention, a strain of bacillus subtilis capable of expressing human active irisin is constructed, and meanwhile, a probiotic oral embedding method is provided, so that the in-vivo activity and effect of the bacillus subtilis are improved. The expression strain not only can express and produce the tectoridin protein with activity and without endotoxin, but also can exert the activity of probiotics through oral administration after embedding.

The invention belongs to the technical field of biological medicine, and discloses application of JAM3 protein in preparation of a medicine for inhibiting formation of a neutrophil extracellular trapping net. JAM3 is an I-type single transmembrane protein containing 310 amino acids, and belongs to an immunoglobulin superfamily. Researches show that the JAM3 protein remarkably inhibits excessive formation of a sepsis neutrophile granulocyte extracellular trapping net by regulating and controlling an activation path of neutrophile granulocytes, and meanwhile prevents blood platelets from being excessively captured, so that formation of microthrombus in the liver and damage to organs are avoided, disease progression is effectively controlled, and recovery of peripheral blood cells and organisms is promoted.

The present invention provides a method for preparing a platelet lysate rich in extracellular vesicles and its application. The platelet lysate prepared by intermittent ultrasonic lysis does not require the exogenous addition of biochemical components such as thrombin, collagen, or calcium ions, making it simpler and safer. By setting reasonable ultrasonic process parameters, the prepared platelet lysate is not only rich in various factors (such as bFGF, VEGF, PDGF-BB, and IL-6, IL-15, IL-17, and INF-γ) but also has a high content of bioactive proteins. Furthermore, the extracellular vesicles are not only high in content but also small in diameter, with an average diameter of as low as 79.9 nm. The proportion of exosomes is relatively large, and the extracellular vesicles have high expression of the transmembrane protein CD9 and low expression of CD81.

The application provides a high-purity human Orai2 membrane protein preparation method based on a mammalian cell expression system. The method obtains a recombinant expression vector containing a human Orai2 gene and an affinity tag sequence; the recombinant expression vector is transfected into a host cell line for expression; a membrane dissolving buffer containing dodecyl-beta-D-maltopyranoside and cholesteryl hemisuccinate is used for lysis extraction of the host cell; after centrifugation to obtain supernatant, the supernatant is sequentially separated and purified by using an affinity chromatography medium and a gel exclusion chromatography medium, and high-purity human Orai2 protein is obtained. The application constructs a thermodynamic equilibrium micellar microenvironment, solves the conformational inactivation problem in the extraction process of multiple transmembrane proteins, and realizes efficient and high-purity enrichment of human Orai2 protein.

The invention belongs to the technical field of biology, and particularly relates to application of interferon-induced transmembrane protein 1 in diagnosis of acute coronary syndrome. The invention discloses a potential value of IFITM1 as a novel serum marker in diagnosis of acute coronary syndrome (ACS). Firstly, it is found through ELISA technology detection that the IFITM1 level in serum of ACS patients is significantly higher than that of healthy people and coronary heart disease patients. Secondly, the level of the IFITM1 is related to the severity of the coronary heart disease, and the ROC analysis result shows that the AUC values of the IFITM1 during CAD diagnosis and ACS diagnosis are 0.9530 and 0.9932 respectively, which indicates that the IFITM1 has very high diagnosis efficiency and can effectively distinguish ACS patients from other groups. The discovery of IFITM1 provides a new auxiliary diagnosis means for clinic, and is helpful for early recognition of ACS patients, so that treatment measures are taken in time, and prognosis of the patients is improved.